What is Cellectar Biosciences Inc Annual Net Profit?

Cellectar Biosciences Inc Annual Net Profit fell 4.23% in the last year to $44.58 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Cellectar Biosciences Inc Price to Earning Ratio?

Cellectar Biosciences Inc Price to Earning Ratio is -0.4, which is negative.

What is Cellectar Biosciences Inc Stock Price?

Cellectar Biosciences Inc Stock Price fell 90.37% and underperformed its sector by 100.27% in the past year.

What is Cellectar Biosciences Inc Quarterly Net profit?

Cellectar Biosciences Inc Quarterly Net profit rose 70.11% YoY to $2.36 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is Cellectar Biosciences Inc Mutual Fund Holding?

Cellectar Biosciences Inc Mutual Fund Holding decreased by 0.39% in the last quarter to 8.37.

What is Cellectar Biosciences Inc Promoter Share Holding?

Cellectar Biosciences Inc Promoter Share Holding increased by 0.32% in the most recent quarter to 3.34%.

What is Cellectar Biosciences Inc Institutional Holding?

Cellectar Biosciences Inc Institutional Holding decreased by 19.32% in the last quarter to 11.33.

How is the Cellectar Biosciences Inc today?

The Cellectar Biosciences Inc today is trading in the green, up by 5.41% at 0.39.

How has Cellectar Biosciences Inc performed historically?

The Cellectar Biosciences Inc is currently trading up 5.41% on an intraday basis in the past week the index rose 21.88%. The index has been up 39.29% in the past quarter and fell -90.37% in the past year. You can view this in the overview section.

Cellectar Biosciences Inc XNAS: CLRB

Cellectar Biosciences Inc Live Share Price Today, Share Analysis and Chart

Name: Cellectar Biosciences Inc: Is Infosys Ltd. worth buying?
Item: Cellectar Biosciences Inc
Rating: 1.01908325
Author: Trendlyne DVM scores

Download real time

0.39 0.02 (5.41%)

90.65% Fall from 52W High

508.8K XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Cellectar Biosciences Inc is on 27 Mar 2025 for the purpose of Cellectar Biosciences Inc Fourth Quarter Earnings Results for 2024 See details

Cellectar Biosciences Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	18
PE TTM Negative PE TTM Unavailable in chosen country	-0.4
PEG TTM Below industry Median Unavailable in chosen country	0.1
Price to Book High in industry Unavailable in chosen country	11.6
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	11.3
Net Profit Qtr Growth YoY % High in industry Unavailable in chosen country	70.1
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-4.2
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	32

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

1.8 / 100

Technically Neutral

38.9 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Cellectar Biosciences Inc Stock Price Analysis

Day Price Range 5.4% 1 Day return Unavailable in chosen country	0.4 (LTP) 0.40.4 LowHigh
Week Price Range 21.9% 1 Week return Unavailable in chosen country	0.4 (LTP) 0.30.4 LowHigh
Month Price Range 25.8% 1 Month return Unavailable in chosen country	0.4 (LTP) 0.30.4 LowHigh
52 Week Price Range -90.4% 1 Year return Unavailable in chosen country	0.4 (LTP) 0.24.2 LowHigh

View full Share Price History

Cellectar Biosciences Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Cellectar Biosciences Inc Stock Analysis

Cellectar Biosciences Inc stock analysis with key metrics, changes, and trends.

Cellectar Biosciences Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$44.58 M	4.23%	negative	Annual Net Profit fell 4.23% in the last year to $44.58 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-0.4	-	negative	Price to Earning Ratio is -0.4, which is negative.
Stock Price	$0.39	-90.37%	negative	Stock Price fell 90.37% and underperformed its sector by 100.27% in the past year.
Quarterly Net profit	$2.36 M	70.11%	positive	Quarterly Net profit rose 70.11% YoY to $2.36 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Mutual Fund Holding	8.37 %	-0.39%	negative	Mutual Fund Holding decreased by 0.39% in the last quarter to 8.37.
Promoter Share Holding	3.34 %	0.32%	positive	Promoter Share Holding increased by 0.32% in the most recent quarter to 3.34%.
Institutional Holding	11.33 %	-19.32%	negative	Institutional Holding decreased by 19.32% in the last quarter to 11.33.

VIEW LESS

Loading data..

Cellectar Biosciences Inc - Company Profile

What does Cellectar Biosciences Inc do?

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Cellectar Biosciences Inc Management structure

All Gross Remunerations are in USD

Mr. James V. Caruso

Director, Chief Executive Officer and President

2024

Gross Remuneration

Year

Mr. Chad J. Kolean

Principal Accounting Officer, Vice President, Secretary and Chief Financial Officer

2024

Gross Remuneration

2024

Gross Remuneration

Year

Cellectar Biosciences Inc Live Share Price Today, Share Analysis and Chart

90.65% Fall from 52W High

Cellectar Biosciences Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Cellectar Biosciences Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Cellectar Biosciences Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Cellectar Biosciences Inc Stock Analysis

Cellectar Biosciences Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 4.23% in the last year to $44.58 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -0.4, which is negative.

Stock Price fell 90.37% and underperformed its sector by 100.27% in the past year.

Quarterly Net profit rose 70.11% YoY to $2.36 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Mutual Fund Holding decreased by 0.39% in the last quarter to 8.37.

Promoter Share Holding increased by 0.32% in the most recent quarter to 3.34%.

Institutional Holding decreased by 19.32% in the last quarter to 11.33.

Cellectar Biosciences Inc - Company Profile

What does Cellectar Biosciences Inc do?

Cellectar Biosciences Inc Management structure

Mr. James V. Caruso

Director, Chief Executive Officer and President

Mr. Chad J. Kolean

Principal Accounting Officer, Vice President, Secretary and Chief Financial Officer

Cellectar Biosciences Inc Board of directors

Mr. Frederick W. Driscoll

Independent Director

Mr. Douglas J Swirsky

Chairman of the Board

Mr. John P. Neis

Independent Director

Mr. James V. Caruso

Director, Chief Executive Officer and President

Dr. Stefan D. Loren, PhD

Independent Director

Dr. Asher Chanan-Khan, M.B.B.S.,M.D.

Independent Director

Cellectar Biosciences Inc FAQ

How is Cellectar Biosciences Inc today?

Cellectar Biosciences Inc today is trading in the green, and is up by 5.41% at 0.39.

How has Cellectar Biosciences Inc performed historically?

Cellectar Biosciences Inc is currently trading up 5.41% on an intraday basis. In the past week the stock rose 21.88%. stock has been up 39.29% in the past quarter and fell -90.37% in the past year. You can view this in the overview section.